Pricing Log in Create free account
Friday 6 November 2026 Export CHE’s income statement to Excel — free account

Chemed Corporation

CHE Healthcare Medical Care Facilities

Chemed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 4.06% from fiscal 2024.

Revenue
+10.6%
EPS
+23.1%
Free cash flow
−45.3%

Quarter to September 2026, against a year earlier

524.81 8.96 −1.68%
Market cap
$7.0B
P/E
25.5×
Fwd P/E
24.0×
Dividend yield
0.47%
F-score
6/9
Altman Z
11.69
Beneish M
−2.76
Dividend safety
100/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Chemed Corporation 10-K filed Feb 27, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 9:36 AM ET · Document on sec.gov · Filing index

Red flags

  • Restatement

    Chemed Corporation’s 10-K corrects an error in previously issued financial statements

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 28, 2025: 4 added · 3 removed · 21 modified; 9 with only figures updated

  1. Modified · VITAS

    Hospice care in the United States is competitive. Plans of care for hospice services are not proprietary. As a result, VITAS competes and differentiates itself primarily on the basis of its ability to deliver quality, responsive services within the requirements of Medicare’s hospice conditions of participation. VITAS is one of the nation’s largest providers of hospice services in an industry dominated primarily by small, community-based hospices. Approximately one quarter20% of all hospice providers are not-for-profit. Because the hospice care industry is highly fragmented, VITAS competes with a large number of organizations.